Evidence map›Paper›PMID 34764870›Full record

ArticleFrontiers in pharmacology2021

Structure-Activity Relationship of Novel Second-Generation Synthetic Cathinones: Mechanism of Action, Locomotion, Reward, and Immediate-Early Genes.

Nuria Nadal-Gratacós, Ana Sofia Alberto-Silva, Míriam Rodríguez-Soler, Edurne Urquizu, Maria Espinosa-Velasco, Kathrin Jäntsch, Marion Holy, Xavier Batllori, Xavier Berzosa, David Pubill and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Structure-Activity Relationship ofACS chemical neuroscience · 2023
    Article
  19. Review
  20. Neuropsychopharmacology of Emerging Drugs of Abuse:International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Nuria Nadal-GratacósDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Ana Sofia Alberto-SilvaCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University Vienna, Vienna, Austria.
Míriam Rodríguez-SolerDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Edurne UrquizuDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Maria Espinosa-VelascoDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Kathrin JäntschCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University Vienna, Vienna, Austria.
Marion HolyCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University Vienna, Vienna, Austria.
Xavier BatlloriPharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
Xavier BerzosaPharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
David PubillDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Jordi CamarasaDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Harald H SitteCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University Vienna, Vienna, Austria.
Elena EscubedoDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Raúl López-ArnauDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, Pharmacology Section and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Universitat de Barcelona · ESUniversitat Ramon Llull · ESMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several new synthetic cathinones, which mimic the effect of classical psychostimulants such as cocaine or MDMA, have appeared in the global illicit drug market in the last decades. In fact, the illicit drug market is continually evolving by constantly adding small modifications to the common chemical structure of synthetic cathinones. Thus, the aim of this study was to investigate the

Indexed as

immediate-early gene (IEG)new psychoactive substancepsychostimulantreleasersrewardstructure–activity relationshipsynthetic cathinones

Identifiers

PMID34764870
PMCPMC8576102
OpenAlexW3210645845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.